GlobeNewsWire
09 Oct 2025, 17:58 UTC · 49w ago
Verdict
Headline takes no side. We score MLTX −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 97% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
MoonLake Immunotherapeutics' Phase 3 VELA-2 trial for sonelokimab failed to achieve statistical significance in its week 16 primary endpoint.
So whatThe failure of a lead drug candidate in Phase 3 is a catastrophic event for a biotech company, as evidenced by the 90% share price collapse.
More negative than 99% of claims this week
Law firm Hagens Berman has opened an investigation into whether MoonLake misled investors regarding the VELA-2 trial design and efficacy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 83% of claims this week
Which stocks this story touches
More negative than 97% of ticker scores this week
The company reported disappointing Phase 3 trial data, leading to a 90% stock price crash and a shareholder fraud investigation.
More negative than 84% of ticker scores this week
The company is mentioned as the subject of an investigation due to a stock plunge following allegedly misleading financial statements.
More negative than 84% of ticker scores this week
The company is mentioned as the subject of an investigation due to a stock plunge following allegedly misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
+36.2%
Price is moving against the score
$12.39 vs $9.10 close before publication (Oct 8) · not market-adjusted
MLTX chart →
